CDK4/6 Inhibitors in HER2+ Metastatic Breast Cancer

Videos

Dr Matthew Goetz addresses the prospect of utilizing CDK4/6 inhibitors to treat patients with HER2+ metastatic breast cancer, stating early data indicate that CDK4/6 inhibitors may have some antitumor activity in HER2+ breast cancer.

Want more Breast Cancer-related news?

Sign up for the OPM weekly e-Newsletter!

Enter your contact information below to recieve weekly oncology news & updates.

Related Articles

Subscribe to
Oncology Practice Management

Stay up to date with oncology news & updates by subscribing to recieve the free OPM print publications or weekly e‑Newsletter.

I'd like to recieve: